Payment overview · 2025
General Payments
$284.85
15 reported records · 7 companies
Healthcare provider profile · identity verified
Abdallah S Dawod, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALTUS, OK · NPI 1174519771
Verified facts
What the public records show
CMS Open Payments records show Abdallah S Dawod, MD received $284.85 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $118.43 | 41.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.31 | 16.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.76 | 14.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.63 | 7.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.17 | 7.8% | 1 | 2025 |
| UROGEN PHARMA, INC. | Unresolved — no canonical attribution shown | $18.86 | 6.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.69 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $284.85 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $70.40 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.03 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.31 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| JELMYTO Normalized: jelmyto |
Drug | UROGEN PHARMA, INC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 260 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
260 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
207 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 665 | 121 |
| Gabapentin | Gabapentin | 631 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 93 |
| Losartan Potassium | Losartan Potassium | 366 | 110 |
| Omeprazole | Omeprazole | 355 | 95 |
| Lisinopril | Lisinopril | 269 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 263 | 61 |
| Tramadol Hcl | Tramadol Hcl | 263 | 47 |
| Mounjaro | Tirzepatide | 260 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 74 |
| Furosemide | Furosemide | 236 | 59 |
| Potassium Chloride | Potassium Chloride | 230 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 61 |
| Ropinirole Hcl | Ropinirole Hcl | 211 | 51 |
| Eliquis | Apixaban | 207 | 31 |
| Meloxicam | Meloxicam | 206 | 48 |
| Celecoxib | Celecoxib | 198 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 193 | 28 |
| Simvastatin | Simvastatin | 191 | 39 |
| Trazodone Hcl | Trazodone Hcl | 183 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 179 | 53 |
| Famotidine | Famotidine | 174 | 40 |
| Glipizide | Glipizide | 166 | 46 |
| Metformin Hcl | Metformin Hcl | 162 | 59 |
| Prednisone | Prednisone | 157 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 45 |
| Sertraline Hcl | Sertraline Hcl | 148 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 33 |
| Carvedilol | Carvedilol | 135 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 50 |
| Montelukast Sodium | Montelukast Sodium | 131 | 33 |
| Buspirone Hcl | Buspirone Hcl | 125 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 29 |
| Donepezil Hcl | Donepezil Hcl | 109 | 23 |
| Ibuprofen | Ibuprofen | 109 | 32 |
| Lorazepam | Lorazepam | 105 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 33 |
| Clonazepam | Clonazepam | 97 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 26 |
| Januvia | Sitagliptin Phosphate | 97 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 22 |
| Ozempic | Semaglutide | 93 | 20 |
| Amoxicillin | Amoxicillin | 91 | 63 |
| Naproxen | Naproxen | 90 | 17 |
| Alprazolam | Alprazolam | 89 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 87 | 14 |
| Allopurinol | Allopurinol | 85 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 45 |
| Sucralfate | Sucralfate | 84 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 18 |
| Levofloxacin | Levofloxacin | 80 | 68 |
| Meclizine Hcl | Meclizine Hcl | 80 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 53 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 23 |
| Ondansetron Odt | Ondansetron | 71 | 38 |
| Metformin Hcl Er | Metformin Hcl | 70 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 19 |
| Temazepam | Temazepam | 68 | 13 |
| Azithromycin | Azithromycin | 67 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 19 |
| Pregabalin | Pregabalin | 60 | 15 |
| Levetiracetam | Levetiracetam | 59 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 38 |
| Trulicity | Dulaglutide | 58 | 13 |
| Diazepam | Diazepam | 56 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 11 |
| Jardiance | Empagliflozin | 54 | 12 |
| Clonidine Hcl | Clonidine Hcl | 53 | 12 |
| Glipizide Er | Glipizide | 51 | 18 |
| Topiramate | Topiramate | 51 | 11 |
| Fluconazole | Fluconazole | 50 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 29 |
| Divalproex Sodium | Divalproex Sodium | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 17 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 30 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Cephalexin | Cephalexin | 34 | 30 |
| Acyclovir | Acyclovir | 33 | 14 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Nystatin | Nystatin | 31 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 28 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Phenytoin | Phenytoin | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Cefprozil | Cefprozil | 23 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 14 |
| Finasteride | Finasteride | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Propylthiouracil | Propylthiouracil | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 12 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 11 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $284.85 · 15 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, COMIRNATY, FARXIGA, JARDIANCE, JELMYTO, MOUNJARO, PENBRAYA, PREVNAR 20, TRUMENBA, The Cologuard Plus Collection Kit, VIBERZI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error